45280-17-9Relevant academic research and scientific papers
A METHOD OF TREATING PERIPHERAL INFLAMMATORY DISEASE
-
Paragraph 0078-0084; 0121-0122, (2016/12/01)
An active for use in the treatment or inhibition of an inflammatory disease associated with over-activation of Toll-like Receptor 4 (TLR4), Toll-like Receptor 2 (TLR2) and Myeloid differentiating protein 88 (Myd88) adaptor-like protein (Mal) while maintaining a subject's ability to respond normally to a pathogen, in which the active is an oleamide or a derivative thereof.
Some features of an SmI2-(Me2N)3P-THF system. Transformation of esters into dimethylamides
Ivanova,Shainurova,Miftakhov
, p. 329 - 331 (2007/10/03)
Sm11-intermediates generated upon addition of (Me2N)3P to a solution of SmI2 in THF exhibit the properties of a single-electron reducing agent and an N-nucleophile. In particular, N,N-dimethylamides are formed from esters.
Arachidonic acid amide inhibitors of gap junction cell-cell communication
Boger, Dale L.,Sato, Haruhiko,Lerner, Aaron E.,Guan, Xiaojun,Gilula, Norton B.
, p. 1151 - 1154 (2007/10/03)
A series of arachidonic acid amides including anandamide and arachidonamide that act as potent inhibitors of the rat glial cell gap junction is described.
Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor
Sheskin, Tzviel,Hanu?, Lumir,Slager, Joram,Vogel, Zvi,Mechoulam, Raphael
, p. 659 - 667 (2007/10/03)
In order to establish the structural requirements for binding to the brain cannabinoid receptor (CB1), we have synthesized numerous fatty acid amides, ethanolamides, and some related simple derivatives and have determined their K(i) values. A f
